Study Details

Open

Anifrolumab in HS

Study how effective and safe anifrolumab is in patients with hidradenitis suppurativa (HS).

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

This is a research study aims to determine if a drug called anifrolumab is safe and effective at treating hidradenitis suppurativa (HS). Anifrolumab is given via an intravenous (i.v.) infusion at UNC. You will have tests, exams and procedures for study purposes. Infusions of study drug will be given monthly, first at 900mg for three months, and then at 600mg for the next three months. Each month you will be evaluated, and you may be able to continue receiving anifrolumab if the study doctor determines that is safe for you to do so. Some visits will require you to fill out questionnaires, and for the study team to obtain a sample of your blood, assess your HS, obtain photographs of your HS, as well as electrocardiograms (EKG), which trace the electrical activity in your heart.

Incentives

$150.00

In-person visits:
10

Total length of participation:
10 months

Looking for Specific Volunteers

Able to participate:

Have had HS for more than 6 months, Hurley Stage II/III and have at least 5 or more active lesions of HS
You have HS in at least two distinct areas in the body (for example, left and right groin).
Are off oral and intravenous antibiotics or on a stable course of oral antibiotics for ≥28 days prior to the baseline visit.
You are no pregnant or breastfeeding or planning to become pregnant or breastfeeding

Not eligible if:

Have an allergy, hypersensitivity, or have previously received anifrolumab
Have a history of cancer (except for certain skin cancers), medically significant infection or immunodeficiency (such as primary immunodeficiency, TB, or HIV).
Have a history of severe COVID that required prolonged hospitalization (hospitalization for observation purposes is fine)
Have severe anemia, severe liver dysfunction, or immunosuppression

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Secondary Visit Location

Dermatology Clinical Trials Unit (DCTU)
UNC Dermatology and Skin Cancer Center at Southern Village
410 Market St Ste 362, Chapel Hill, NC 27516, USA

Additional Study Information

Principal Investigator

Chris Sayed
Dermatology-Research

Study Type

Clinical or Medical
Interventional

Study Topics

Minority Health
Rare Diseases
Skin, Hair, and Nails

IRB Number

24-0191